It is now well established that castration-resistant disease can be effectively treated using newer androgen receptor-targeting agents such as abiraterone and enzalutamide.
Celestia S. Higano, MD
Advertisement
Articles by Celestia S. Higano, MD
Advertisement
Latest Updated Articles
- Targeting the Androgen Receptor Signaling Axis to Reduce Testosterone Levels in Prostate Cancer: How Low Should We Go?
Published: August 15th 2014 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Could Scorpion Venom Component Play a Role in Glioblastoma Management?
2
How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research
3
Chlorotoxin-Directed Cell Therapy May Have Useful Mechanism in Glioblastoma
4
Novel IL-2 Therapy Combo Yields Initial Responses in Nonsquamous NSCLC
5
